These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 18440274)

  • 1. Immunotherapy for antineutrophil cytoplasmic antibody-associated vasculitis: challenging the therapeutic status quo?
    Bosch X; Guilabert A; Espinosa G; Mirapeix E
    Trends Immunol; 2008 Jun; 29(6):280-9. PubMed ID: 18440274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current state of biologicals in the management of systemic vasculitis.
    Lamprecht P; Till A; Steinmann J; Aries PM; Gross WL
    Ann N Y Acad Sci; 2007 Sep; 1110():261-70. PubMed ID: 17911441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathogenesis of PR3-ANCA associated vasculitis.
    Kallenberg CG
    J Autoimmun; 2008; 30(1-2):29-36. PubMed ID: 18162369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Translating basic science into patient therapy for ANCA-associated small vessel vasculitis.
    Williams JM; Kamesh L; Savage CO
    Clin Sci (Lond); 2005 Feb; 108(2):101-12. PubMed ID: 15504102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is there a role for TNF-alpha in anti-neutrophil cytoplasmic antibody-associated vasculitis? Lessons from other chronic inflammatory diseases.
    Feldmann M; Pusey CD
    J Am Soc Nephrol; 2006 May; 17(5):1243-52. PubMed ID: 16624928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The importance of resolution of inflammation in the pathogenesis of ANCA-associated vasculitis.
    Harper L; Williams JM; Savage CO
    Biochem Soc Trans; 2004 Jun; 32(Pt3):502-6. PubMed ID: 15157172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autoantibodies to neutrophil granule proteins: pathogenic potential in vasculitis?
    Locke IC; Cambridge G
    Br J Biomed Sci; 1996 Dec; 53(4):302-16. PubMed ID: 9069109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complement Factor H Inhibits Anti-Neutrophil Cytoplasmic Autoantibody-Induced Neutrophil Activation by Interacting With Neutrophils.
    Chen SF; Wang FM; Li ZY; Yu F; Chen M; Zhao MH
    Front Immunol; 2018; 9():559. PubMed ID: 29616045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coexpression of CD177 and membrane proteinase 3 on neutrophils in antineutrophil cytoplasmic autoantibody-associated systemic vasculitis: anti-proteinase 3-mediated neutrophil activation is independent of the role of CD177-expressing neutrophils.
    Hu N; Westra J; Huitema MG; Bijl M; Brouwer E; Stegeman CA; Heeringa P; Limburg PC; Kallenberg CG
    Arthritis Rheum; 2009 May; 60(5):1548-57. PubMed ID: 19404956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathophysiology of ANCA-associated vasculitides: are ANCA really pathogenic?
    Tervaert JW; Heeringa P
    Neth J Med; 2003 Dec; 61(12):404-7. PubMed ID: 15025415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential immunosuppressive therapeutics to target small vessel vasculitis of the kidney.
    Williams JM
    Curr Opin Investig Drugs; 2005 Nov; 6(11):1142-8. PubMed ID: 16312136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ANCA-associated vasculitides: pathogenetic aspects and current evidence-based therapy.
    Holle JU; Gross WL
    J Autoimmun; 2009; 32(3-4):163-71. PubMed ID: 19345067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MPO-ANCA induces IL-17 production by activated neutrophils in vitro via classical complement pathway-dependent manner.
    Hoshino A; Nagao T; Nagi-Miura N; Ohno N; Yasuhara M; Yamamoto K; Nakayama T; Suzuki K
    J Autoimmun; 2008 Aug; 31(1):79-89. PubMed ID: 18501296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contribution of myeloperoxidase in vasculitis development.
    Suzuki K; Okazaki T
    Jpn J Infect Dis; 2004 Oct; 57(5):S2-3. PubMed ID: 15507759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased membrane expression of proteinase 3 during neutrophil adhesion in the presence of anti proteinase 3 antibodies.
    Brachemi S; Mambole A; Fakhouri F; Mouthon L; Guillevin L; Lesavre P; Halbwachs-Mecarelli L
    J Am Soc Nephrol; 2007 Aug; 18(8):2330-9. PubMed ID: 17634439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating neutrophil gelatinase-associated lipocalin: a useful biomarker for assessing disease activity of ANCA-associated vasculitis.
    Chen M; Wang F; Zhao MH
    Rheumatology (Oxford); 2009 Apr; 48(4):355-8. PubMed ID: 19181656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathogenesis of vascular inflammation by anti-neutrophil cytoplasmic antibodies.
    Jennette JC; Xiao H; Falk RJ
    J Am Soc Nephrol; 2006 May; 17(5):1235-42. PubMed ID: 16624929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathogenesis of ANCA-associated vasculitis.
    Flint J; Morgan MD; Savage CO
    Rheum Dis Clin North Am; 2010 Aug; 36(3):463-77. PubMed ID: 20688244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune regulatory mechanisms in ANCA-associated vasculitides.
    Lepse N; Abdulahad WH; Kallenberg CG; Heeringa P
    Autoimmun Rev; 2011 Dec; 11(2):77-83. PubMed ID: 21856453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term treatment results and the immunoglobulin G subclass distribution patterns of proteinase-3-antineutrophil cytoplasm antibody (ANCA) and myeloperoxidase-ANCA in ANCA-associated vasculitis.
    Almroth G; Berlin G; Andersson B; Hahn-Zoric M
    Scand J Urol Nephrol; 2009; 43(2):160-70. PubMed ID: 18979374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.